Sign in or create an account to add this stock to your watchlist.
About Revance Therapeutics (NASDAQ:RVNC)
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. Revance Therapeutics, Inc. has a collaboration agreement with Mylan N.V. (MYL) for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RVNC
CUSIPN/A
Phone510-742-3400
Debt
Debt-to-Equity RatioN/A
Current Ratio11.89
Quick Ratio11.89
Price-To-Earnings
Trailing P/E Ratio-7.57
Forward P/E Ratio-7.80
P/E GrowthN/A
Sales & Book Value
Annual Sales$260,000.00
Price / Sales4,293.36
Cash FlowN/A
Price / CashN/A
Book Value$7.51 per share
Price / Book4.04
Profitability
EPS (Most Recent Fiscal Year)($4.01)
Net Income$-120,580,000.00
Net Margins-33,807.37%
Return on Equity-63.68%
Return on Assets-54.86%
Miscellaneous
Employees134
Outstanding Shares36,780,000
Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions
What is Revance Therapeutics' stock symbol?
Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."
How were Revance Therapeutics' earnings last quarter?
Revance Therapeutics Inc. (NASDAQ:RVNC) released its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.97) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by $0.26. The biopharmaceutical company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.15 million. Revance Therapeutics had a negative net margin of 33,807.37% and a negative return on equity of 63.68%. View Revance Therapeutics' Earnings History.
What price target have analysts set for RVNC?
12 brokers have issued 1-year price targets for Revance Therapeutics' stock. Their forecasts range from $34.00 to $60.00. On average, they expect Revance Therapeutics' share price to reach $46.1818 in the next twelve months. View Analyst Ratings for Revance Therapeutics.
What are Wall Street analysts saying about Revance Therapeutics stock?
Here are some recent quotes from research analysts about Revance Therapeutics stock:
- 1. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (5/15/2018)
- 2. Cantor Fitzgerald analysts commented, "Today, RVNC announced four new senior roles for its commercialization team: Dustin Sjuts as VP Strategy and Sales, Aesthetics & Therapeutics; Ben Putman as VP Digital; Marc Korenberg as Sr Director of Commercial Operations; and Erica Bazerkanian has been promoted to VP Marketing, Aesthetics & Therapeutics." (4/2/2018)
Who are some of Revance Therapeutics' key competitors?
Some companies that are related to Revance Therapeutics include Taro Pharmaceutical Industries (TARO), Hutchison China MediTech (HCM), GW Pharmaceuticals (GWPH), FibroGen (FGEN), Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS) and Tesaro (TSRO).
Who are Revance Therapeutics' key executives?
Revance Therapeutics' management team includes the folowing people:
- Mr. L. Daniel Browne, Co-Founder, CEO, Pres & Director (Age 56)
- Dr. Abhay Joshi, Chief Operating Officer (Age 55)
- Mr. Todd Erik Zavodnick, Chief Commercial Officer and Pres of Aesthetics & Therapeutics (Age 46)
- Ms. Lauren P. Silvernail, CFO, Chief Bus. Officer & Sec. (Age 59)
- Jeanie D. Herbert, Sr. Director of Investor Relations & Corp. Communications
Has Revance Therapeutics been receiving favorable news coverage?
Headlines about RVNC stock have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Revance Therapeutics earned a media sentiment score of 0.11 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.76 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Revance Therapeutics' major shareholders?
Revance Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (9.36%), Franklin Resources Inc. (8.64%), BlackRock Inc. (6.56%), Millennium Management LLC (4.06%), Northern Trust Corp (0.92%) and Fosun International Ltd (0.87%). Company insiders that own Revance Therapeutics stock include Curtis Ruegg, L Daniel Browne, Lauren P Silvernail, Mark J Foley and Phyllis Gardner. View Institutional Ownership Trends for Revance Therapeutics.
Which major investors are selling Revance Therapeutics stock?
RVNC stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., JPMorgan Chase & Co., BNP Paribas Arbitrage SA, Rothschild Asset Management Inc. and Blair William & Co. IL. Company insiders that have sold Revance Therapeutics company stock in the last year include L Daniel Browne, Lauren P Silvernail and Phyllis Gardner. View Insider Buying and Selling for Revance Therapeutics.
Which major investors are buying Revance Therapeutics stock?
RVNC stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Fosun International Ltd, BlackRock Inc., OppenheimerFunds Inc., Northern Trust Corp, DekaBank Deutsche Girozentrale, Federated Investors Inc. PA and Candriam Luxembourg S.C.A.. View Insider Buying and Selling for Revance Therapeutics.
How do I buy shares of Revance Therapeutics?
Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Revance Therapeutics' stock price today?
One share of RVNC stock can currently be purchased for approximately $30.35.
How big of a company is Revance Therapeutics?
Revance Therapeutics has a market capitalization of $1.13 billion and generates $260,000.00 in revenue each year. The biopharmaceutical company earns $-120,580,000.00 in net income (profit) each year or ($4.01) on an earnings per share basis. Revance Therapeutics employs 134 workers across the globe.
How can I contact Revance Therapeutics?
Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-742-3400 or via email at [email protected]
MarketBeat Community Rating for Revance Therapeutics (RVNC)
MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote "Outperform" if you believe RVNC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RVNC will underperform the S&P 500 over the long term. You may vote once every thirty days.
Revance Therapeutics (NASDAQ:RVNC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
12 Wall Street analysts have issued ratings and price targets for Revance Therapeutics in the last 12 months. Their average twelve-month price target is $46.1818, suggesting that the stock has a possible upside of 52.16%. The high price target for RVNC is $60.00 and the low price target for RVNC is $34.00. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.92 | 2.92 | 2.89 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $46.1818 | $46.1818 | $46.1111 | $37.00 |
| Price Target Upside: | 52.16% upside | 50.09% upside | 37.24% upside | 45.10% upside |
Revance Therapeutics (NASDAQ:RVNC) Consensus Price Target History
Revance Therapeutics (NASDAQ:RVNC) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
Revance Therapeutics (NASDAQ:RVNC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Revance Therapeutics (NASDAQ RVNC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.05%
Institutional Ownership Percentage: 92.85%
Revance Therapeutics (NASDAQ RVNC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/22/2018 | Lauren P Silvernail | CFO | Sell | 3,431 | $30.85 | $105,846.35 | 68,371 |  |
| 3/16/2018 | L Daniel Browne | CEO | Sell | 6,452 | $31.64 | $204,141.28 | 130,208 | |
| 3/16/2018 | Phyllis Gardner | Director | Sell | 5,333 | $31.51 | $168,042.83 | 5,250 | |
| 3/13/2018 | Lauren P Silvernail | CFO | Sell | 25,867 | $34.50 | $892,411.50 | 98,821 | |
| 3/9/2018 | Lauren P Silvernail | CFO | Sell | 20,000 | $32.00 | $640,000.00 | 82,954 | |
| 3/7/2018 | L Daniel Browne | CEO | Sell | 27,283 | $31.43 | $857,504.69 | 131,208 | |
| 3/7/2018 | Lauren P Silvernail | CFO | Sell | 10,000 | $31.50 | $315,000.00 | 82,954 | |
| 11/22/2017 | L Daniel Browne | CEO | Sell | 7,600 | $24.94 | $189,544.00 | 133,188 | |
| 11/7/2017 | Lauren P Silvernail | CFO | Sell | 10,000 | $26.83 | $268,300.00 | 59,006 | |
| 11/7/2017 | Mark J Foley | Director | Buy | 20,000 | $26.96 | $539,200.00 | 6,000 | |
| 10/18/2017 | L Daniel Browne | CEO | Sell | 7,662 | $26.16 | $200,437.92 | 140,788 | |
| 10/12/2017 | Lauren P Silvernail | CFO | Sell | 11,164 | $26.67 | $297,743.88 | | |
| 9/20/2017 | L Daniel Browne | CEO | Sell | 7,600 | $23.58 | $179,208.00 | 148,450 | |
| 8/23/2017 | L Daniel Browne | CEO | Sell | 22,800 | $22.76 | $518,928.00 | 178,850 | |
| 5/24/2017 | L Daniel Browne | CEO | Sell | 19,713 | $20.35 | $401,159.55 | 183,932 | |
| 5/22/2017 | L Daniel Browne | CEO | Sell | 12,287 | $20.20 | $248,197.40 | 183,932 | |
| 5/22/2017 | Lauren P Silvernail | CFO | Sell | 1,793 | $20.20 | $36,218.60 | 36,566 | |
| 1/25/2017 | L Daniel Browne | CEO | Sell | 12,000 | $19.78 | $237,360.00 | 184,627 | |
| 12/28/2016 | L Daniel Browne | CEO | Sell | 12,000 | $20.94 | $251,280.00 | 195,627 | |
| 11/25/2016 | L Daniel Browne | CEO | Sell | 12,000 | $17.92 | $215,040.00 | 208,449 | |
| 10/26/2016 | L Daniel Browne | CEO | Sell | 12,000 | $14.85 | $178,200.00 | 219,627 | |
| 6/13/2016 | Curtis Ruegg | EVP | Sell | 1,000 | $18.25 | $18,250.00 | 24,944 | |
| 5/9/2016 | Curtis Ruegg | EVP | Sell | 1,000 | $16.18 | $16,180.00 | 26,264 | |
| 4/11/2016 | Curtis Ruegg | EVP | Sell | 1,000 | $19.11 | $19,110.00 | 26,264 | |
| 3/7/2016 | Curtis Ruegg | EVP | Sell | 1,000 | $20.43 | $20,430.00 | 26,264 | |
| 2/8/2016 | Curtis Ruegg | EVP | Sell | 1,000 | $18.14 | $18,140.00 | 17,264 | |
| 1/6/2016 | Curtis Ruegg | EVP | Sell | 2,000 | $33.06 | $66,120.00 | 18,027 | |
| 11/17/2015 | Arthur Peter Bertolino | EVP | Sell | 7,753 | $39.11 | $303,219.83 | 34,001 | |
| 8/17/2015 | Curtis Ruegg | EVP | Sell | 3,000 | $30.33 | $90,990.00 | 18,027 | |
| 7/17/2015 | Curtis Ruegg | EVP | Sell | 3,000 | $31.03 | $93,090.00 | | |
| 6/17/2015 | Curtis Ruegg | EVP | Sell | 3,000 | $33.53 | $100,590.00 | | |
| 5/18/2015 | Curtis Ruegg | EVP | Sell | 3,000 | $26.42 | $79,260.00 | | |
| 4/17/2015 | Curtis Ruegg | EVP | Sell | 2,000 | $22.23 | $44,460.00 | | |
| 3/17/2015 | Curtis Ruegg | EVP | Sell | 1,500 | $18.61 | $27,915.00 | | |
| 3/9/2015 | Curtis Ruegg | EVP | Sell | 500 | $18.00 | $9,000.00 | | |
| 2/17/2015 | Curtis Ruegg | EVP | Sell | 1,000 | $16.80 | $16,800.00 | | |
| 1/20/2015 | Curtis Ruegg | EVP | Sell | 1,000 | $17.25 | $17,250.00 | | |
| 12/17/2014 | Curtis Ruegg | EVP | Sell | 1,000 | $16.45 | $16,450.00 | | |
| 11/28/2014 | L Daniel Browne | CEO | Buy | 6,000 | $16.67 | $100,020.00 | | |
| 11/18/2014 | Curtis Ruegg | EVP | Sell | 1,000 | $16.00 | $16,000.00 | | |
| 9/17/2014 | Curtis Ruegg | EVP | Sell | 2,000 | $20.55 | $41,100.00 | | |
| 9/17/2014 | Jacob Waugh | Insider | Sell | 97,713 | $20.73 | $2,025,590.49 | | |
(Data available from 1/1/2013 forward)
Revance Therapeutics (NASDAQ RVNC) News Headlines
| Source: |
|
Revance Therapeutics (NASDAQ:RVNC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Revance Therapeutics (NASDAQ:RVNC) Income Statement, Balance Sheet and Cash Flow Statement
Revance Therapeutics (NASDAQ RVNC) Stock Chart for Monday, May, 21, 2018
Loading chart…
